Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Numerate, a biotechnology company specialized in computational methods for making the drug design process has signed research collaboration deal with Boehringer Ingelheim (Canada).
Subscribe to our email newsletter
The collaboration will make use of Numerate’s silico drug design technology to develop novel small molecule drug leads for an undisclosed infectious disease target.
Numerate’s drug design platform comprises a set of algorithms that provide predictive models for molecular properties with accuracies comparable to laboratory testing.
Numerate CEO Guido Lanza said their computational drug design methods would help reduce the time and cost of delivering new lead-stage, small molecule drug candidates for Boehringer Ingelheim.
"This collaboration is the latest in our growing number of partnerships with pharmaceutical companies that are looking to Numerate’s comprehensive in silico drug design technology to help them increase their success rate in generating novel, patentable small molecule leads," Lanza added.